{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2006"],"condition":["Colon cancer","Colorectal cancer","Colorectal Neoplasms"],"disease":["Colon Cancer","Colorectal Cancer","Colorectal Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2028057"],"location":["United States"],"study_start_month":["3"],"keyword":["Irinotecan","Oxaliplatin","Rectal cancer","Capecitabine","NSABP","Bevacizumab"],"repository":["ECRIN MDR"],"study_status":["Terminated"],"additional_accession":[]},"is_claimable":false,"name":"Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon","description":"Bevacizumab is an angiogenesis inhibitor which means it works to stop blood vessel formation in tumors. Without new blood vessels, the growth of a tumor is slowed. Chemotherapy works to kill cancer cells directly. This study is being done to see how colorectal cancer responds to treatment with the combination of bevacizumab and chemotherapy.","dates":{"creation":"2006-03-15"},"accession":"2028057","cross_references":{"ClinicalTrials___gov":["NCT00314353"]}}